{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T19:16:59Z","timestamp":1773861419415,"version":"3.50.1"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Affiliated Traditional Chinese Medicine Hospital,Southwest Medical University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40291-025-00827-0","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:53:43Z","timestamp":1769500423000},"page":"377-378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comment on: \u201cPersonalized Medicine in Cystic Fibrosis: Characterization of Eight Rare CFTR Variants in Intestinal Organoids and Cellular Models\u201d"],"prefix":"10.1007","volume":"30","author":[{"given":"DuJiang","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0027-0572","authenticated-orcid":false,"given":"GuoYou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"827_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-025-00806-5","author":"V Railean","year":"2025","unstructured":"Railean V, Rodrigues CS, Pankonien I, et al. Personalized medicine in cystic fibrosis: characterization of eight rare CFTR variants in intestinal organoids and cellular models. Mol Diagn Ther. 2025. https:\/\/doi.org\/10.1007\/s40291-025-00806-5.","journal-title":"Mol Diagn Ther"},{"issue":"3","key":"827_CR2","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","volume":"13","author":"C Keating","year":"2025","unstructured":"Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, et al. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med. 2025;13(3):256\u201371. https:\/\/doi.org\/10.1016\/S2213-2600(24)00411-9.","journal-title":"Lancet Respir Med"},{"issue":"11","key":"827_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010966.pub4","volume":"11","author":"M Heneghan","year":"2023","unstructured":"Heneghan M, Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2023;11(11):CD010966. https:\/\/doi.org\/10.1002\/14651858.CD010966.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"827_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00018-016-2391-y","volume":"74","author":"V Saint-Criq","year":"2017","unstructured":"Saint-Criq V, Gray MA. Role of CFTR in epithelial physiology. Cell Mol Life Sci. 2017;74(1):93\u2013115. https:\/\/doi.org\/10.1007\/s00018-016-2391-y.","journal-title":"Cell Mol Life Sci"},{"issue":"12","key":"827_CR5","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S2213-2600(24)00205-4","volume":"12","author":"GM Solomon","year":"2024","unstructured":"Solomon GM, Linnemann RW, Rich R, Streby A, Buehler B, Hunter E, et al. Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial. Lancet Respir Med. 2024;12(12):947\u201357. https:\/\/doi.org\/10.1016\/S2213-2600(24)00205-4.","journal-title":"Lancet Respir Med"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-025-00827-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-025-00827-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-025-00827-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:33:29Z","timestamp":1773822809000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-025-00827-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["827"],"URL":"https:\/\/doi.org\/10.1007\/s40291-025-00827-0","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this letter.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"No data were generated or analyzed for or in support of this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"YDJ: conceptualization, methodology, writing\u2014original draft preparation, and supervision; WGY: project administration, funding acquisition, and supervision. All authors have read and agreed to the final version of the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"None of the authors (D.Y. and G.W.) have any conflicts of interest or financial ties to disclose.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}